Companies › MediciNova
2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MN-001 (tipelukast) Cysteinyl leukotriene receptor antagonist | CYSLTR1 | Phase 2 | Diabetes Mellitus, Type 2 | Dec 2026 |
| Ibudilast (MN-166) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Amyotrophic Lateral Sclerosis | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05464784 | MN-001 (tipelukast) | Phase 2 | Diabetes Mellitus, Type 2 | Metabolic and endocrine | Dec 2026 |
| NCT04057898 | Ibudilast (MN-166) | Phase 2 | Amyotrophic Lateral Sclerosis | Neurology | Apr 2027 |
Cash of $25m on 2026-06-30; operating cash outflow about $11m a year; runway about 28 months at that burn, to Oct 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Corxel Pharmaceuticals Shenzhen Wingor Biotechnology NeuroBiogen Urovant Sciences SAb Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.